In recent days, Cathie Wood’s ARK Invest has materially increased its holdings in Beam Therapeutics, adding more than 195,000 shares across its genomics-focused funds as it leans further into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback